Company news
Neuren Pharmaceuticals Limited news in 2020
Neuren Pharmaceuticals Limited's news releases, calls and decks from 2020, newest first.
Positive opinion for all 3 Orphan applications in Europe
December 6, 2020
Approval received for final stage of NNZ-2591 clinical trial
November 18, 2020
Quarterly report and cash flow statement for Q3 2020
October 28, 2020
Neuren initiates manufacture of NNZ-2591 for Phase 2 trials
September 22, 2020
Q2 2020 Activity Report and Cash Flow Report
July 27, 2020
Proposed issue of Securities - NEU
June 28, 2020
Neuren successfully completes $20m capital raising
June 28, 2020
Temporary enrolment pause ended in Phase 3 trial in the US
June 15, 2020
Neuren announces changes to leadership team
May 26, 2020
Neuren commences first clinical trial for NNZ-2591
May 7, 2020
Appendix 4C - quarterly
April 17, 2020
Q1 2020 Activity Report
April 16, 2020
First patent in Israel granted for trofinetide
April 1, 2020
Temporary pause in new enrolments for LAVENDER trial in US
March 23, 2020
Neuren to capture substantially greater value after Phase 3
March 16, 2020
Compelling results for 2591 dose ranging study in PMS model
March 5, 2020
Commentary on potential benefit to Neuren of RPD designation
March 3, 2020
Rare Pediatric Disease designation received from FDA
March 3, 2020
Appendix 4E and 2019 full year accounts
February 25, 2020
Update on trofinetide Phase 3 trial in Rett syndrome
February 19, 2020
Decks in 2020
- Investor Presentation (August 2020)
Investor deck · 32 slides · Aug 18, 2020
- Shareholder Meeting (June 2020)
Shareholder meeting · 22 slides · Jun 29, 2020
- Investor Presentation (April 2020)
Investor deck · 38 slides · Apr 6, 2020